Charles River Laboratories International (CRL) Cash & Equivalents (2009 - 2025)

Charles River Laboratories International's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $213.8 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 9.85% year-over-year to $213.8 million; the TTM figure through Dec 2025 stood at $213.8 million (up 9.85% YoY), while the FY2025 annual figure was $213.8 million, up 9.85% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $213.8 million, up from $207.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $465.4 million in Q1 2021, with the low at $157.2 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $211.4 million (2021), against an average of $229.6 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 48.03% in 2022, then soared 62.23% in 2024.
• Charles River Laboratories International's Cash & Equivalents stood at $241.2 million in 2021, then retreated by 3.03% to $233.9 million in 2022, then rose by 18.32% to $276.8 million in 2023, then decreased by 29.69% to $194.6 million in 2024, then rose by 9.85% to $213.8 million in 2025.
• Business Quant data shows CRL's Cash & Equivalents at $213.8 million in Q4 2025, $207.1 million in Q3 2025, and $182.8 million in Q2 2025.